Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04509037 · ClinicalTrials.gov registry record
Evaluation of Breast Reduction Techniques
A clinical trial of Breast Reductions, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- 490
- Enrollment target
- 1
- Study location
NCT04509037: Recruiting study of Breast Reductions, sponsored by Henry Ford Health System.
NCT04509037 is a study of Breast Reductions that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 490 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04509037, a study of Breast Reductions, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- 490 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to retrospectively evaluate breast reduction techniques in terms of complications, functionality, patient satisfaction, and cosmetic outcomes.
Conditions Studied
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2012-08-08 |
| Est. Completion | 2026-06-12 |
What NCT04509037 shows while recruiting
NCT04509037 is an observational study that tracks outcomes without assigning an intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Breast Reductions appearing as the primary indexed condition, and to 0 interventions.
NCT04509037 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04509037 about?
NCT04509037 is a clinical study titled "Evaluation of Breast Reduction Techniques". The purpose of this study is to retrospectively evaluate breast reduction techniques in terms of complications, functionality, patient satisfaction, and cosmetic outcomes.
What is the current status of trial NCT04509037?
This trial is currently recruiting. The enrollment target is 490 participants. The study started on 2012-08-08. Estimated completion is 2026-06-12.
What conditions does trial NCT04509037 study?
This clinical trial studies the following conditions: Breast Reductions.
Who is sponsoring clinical trial NCT04509037?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04509037 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Reductions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI